Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and Telmisartan

Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and Telmisartan | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and Telmisartan SUSHRUT GUPTA, AMIT PASARI, PRASAD GURJAR, SUNNY MALDE, TWINKLE PAWAR, and 7 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7053853/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Diabetic nephropathy (DN) remains a leading cause of end-stage renal disease (ESRD), with persistent proteinuria contributing to renal and cardiovascular complications. Despite dual therapy with renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose co-transporter-2 inhibitors (SGLT2is), residual proteinuria persists in a substantial subset of patients. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist (MRA), has shown promise in reducing albuminuria and slowing chronic kidney disease (CKD) progression. Unlike previous trials such as FIDELIO-DKD, this study evaluated the additive effect of finerenone exclusively in patients receiving maximum tolerable doses of both dapagliflozin and telmisartan. Objectives To evaluate the efficacy and safety of finerenone in reducing proteinuria in patients with DN and residual albuminuria, all of whom were receiving maximally tolerated background therapy with dapagliflozin and telmisartan. Methods This was a Retrospective, single-center observational study involving 33 patients with diabetic nephropathy and residual proteinuria. All patients received finerenone 10 mg daily for 24 weeks. Key parameters assessed at baseline and follow-up included urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and serum potassium. Responders were defined as patients who exhibited a reduction in UACR at follow-up. Results The mean individual percentage change in UACR was − 7.3%. Twenty-two patients (66.7%) responded to treatment with a reduction in UACR, while 11 patients (33.3%) did not. When stratified by baseline albuminuria, responders with initial UACR 3000 mg/g showed average reductions of − 47.9%, − 39.0%, and − 32.8%, respectively, suggesting a gradient treatment effect. Finerenone was well tolerated. Mild hyperkalaemia (serum potassium > 5.0 mmol/L) occurred in 15.2% of patients, with no cases requiring treatment discontinuation. Renal function remained stable throughout the study. Conclusions Finerenone demonstrated clinically meaningful reductions in proteinuria, particularly in patients with moderate to severe baseline albuminuria, and was generally safe and well tolerated. These findings support the use of finerenone as part of a personalized, multimodal strategy for proteinuria management in diabetic nephropathy, particularly in patients already receiving optimized RAAS and SGLT2 inhibition. Future studies should further define predictors of response and assess long-term renal outcomes. Diabetic nephropathy Finerenone Proteinuria Albuminuria Dapagliflozin Urinary albumin-to-creatinine ratio chronic kidney disease Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7053853","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":485894334,"identity":"8b823cdd-ca9d-4acb-9520-c0e14fdf3900","order_by":0,"name":"SUSHRUT GUPTA","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"SUSHRUT","middleName":"","lastName":"GUPTA","suffix":""},{"id":485894335,"identity":"8f43ca2e-1f85-4e21-ac1a-508ffab1f1df","order_by":1,"name":"AMIT PASARI","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA3ElEQVRIie3NMQuCQBTA8SdCLuY1ngT2FZQDW/wwTwJbmsVRCPQr6LcQgmah9Wg2WmrIqaEp2uqEqM2uLej+cG843o8HoFL9YrV4CIFDAAbPLy2VIBgxO/2KAG7Cqn6RD1n7zak63nTGmll7uCQwIaBnhz5ibyO/QRw4fhNNvYKDV6Za7vYRl0NHTCamPx5mgG6tZbSfGFdBaLgq5ldZYnZX3LCiC8krNjfjBiNklJ9ju+DUK5cfiMWN9e4W3B2Sz9f0kgQTYuRtL3k3wm6KZV1uX0Rq6VWVSqX6sx7XuEmyLB8sFgAAAABJRU5ErkJggg==","orcid":"","institution":"SARASWATI KIDNEY CARE CENTRE","correspondingAuthor":true,"prefix":"","firstName":"AMIT","middleName":"","lastName":"PASARI","suffix":""},{"id":485894336,"identity":"9a36c628-9916-4ec3-a90b-d3f47cb04a9d","order_by":2,"name":"PRASAD GURJAR","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"PRASAD","middleName":"","lastName":"GURJAR","suffix":""},{"id":485894337,"identity":"db67b5bc-81a2-45dd-b1ba-2cd35c05b2e8","order_by":3,"name":"SUNNY MALDE","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"SUNNY","middleName":"","lastName":"MALDE","suffix":""},{"id":485894338,"identity":"dbb9154d-0365-447d-bbc0-e495b28317f4","order_by":4,"name":"TWINKLE PAWAR","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"TWINKLE","middleName":"","lastName":"PAWAR","suffix":""},{"id":485894339,"identity":"9d4a424c-ab3d-41c4-8ca1-cb6cfdf3d647","order_by":5,"name":"VIJAY JEYACHANDRAN","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"VIJAY","middleName":"","lastName":"JEYACHANDRAN","suffix":""},{"id":485894340,"identity":"3bd5fc0a-f3e5-4b8b-9fd6-94ad260408f2","order_by":6,"name":"PRANJAL KASHIV","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"PRANJAL","middleName":"","lastName":"KASHIV","suffix":""},{"id":485894341,"identity":"fb14ba9f-4d16-436c-8309-f66ad47f040f","order_by":7,"name":"SHUBHAM DUBEY","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"SHUBHAM","middleName":"","lastName":"DUBEY","suffix":""},{"id":485894342,"identity":"3066f797-dc03-411e-a228-a9c1667edd0d","order_by":8,"name":"MOHIT KURUNDWADKAR","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"MOHIT","middleName":"","lastName":"KURUNDWADKAR","suffix":""},{"id":485894343,"identity":"8593b479-2b80-42e4-a1df-ea68e57b2253","order_by":9,"name":"KAPIL SEJPAL","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"KAPIL","middleName":"","lastName":"SEJPAL","suffix":""},{"id":485894344,"identity":"269a6d3f-e029-4388-9389-6a32d1fcc1a7","order_by":10,"name":"CHARULATA BAWANKULE","email":"","orcid":"","institution":"SARASWATI KIDNEY CARE CENTRE","correspondingAuthor":false,"prefix":"","firstName":"CHARULATA","middleName":"","lastName":"BAWANKULE","suffix":""},{"id":485894345,"identity":"2730e134-0a96-4c1d-86d1-635abce331df","order_by":11,"name":"MANISH BALWANI","email":"","orcid":"","institution":"Datta Meghe Institute of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"MANISH","middleName":"","lastName":"BALWANI","suffix":""}],"badges":[],"createdAt":"2025-07-05 15:08:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7053853/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7053853/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":96363393,"identity":"a9734f20-0598-4710-ad0c-ceb32ad99cfd","added_by":"auto","created_at":"2025-11-20 10:06:35","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":855347,"visible":true,"origin":"","legend":"","description":"","filename":"FinerenonePAPER21.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7053853/v1_covered_02ae4cea-5c68-467c-b8ff-87c443db91e6.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and Telmisartan","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Diabetic nephropathy, Finerenone, Proteinuria, Albuminuria, Dapagliflozin, Urinary albumin-to-creatinine ratio, chronic kidney disease","lastPublishedDoi":"10.21203/rs.3.rs-7053853/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7053853/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003eDiabetic nephropathy (DN) remains a leading cause of end-stage renal disease (ESRD), with persistent proteinuria contributing to renal and cardiovascular complications. Despite dual therapy with renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose co-transporter-2 inhibitors (SGLT2is), residual proteinuria persists in a substantial subset of patients. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist (MRA), has shown promise in reducing albuminuria and slowing chronic kidney disease (CKD) progression. Unlike previous trials such as FIDELIO-DKD, this study evaluated the additive effect of finerenone exclusively in patients receiving maximum tolerable doses of both dapagliflozin and telmisartan.\u003c/p\u003e\u003ch2\u003eObjectives\u003c/h2\u003e\u003cp\u003eTo evaluate the efficacy and safety of finerenone in reducing proteinuria in patients with DN and residual albuminuria, all of whom were receiving maximally tolerated background therapy with dapagliflozin and telmisartan.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e\u003cp\u003eThis was a Retrospective, single-center observational study involving 33 patients with diabetic nephropathy and residual proteinuria. All patients received finerenone 10 mg daily for 24 weeks. Key parameters assessed at baseline and follow-up included urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and serum potassium. Responders were defined as patients who exhibited a reduction in UACR at follow-up.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003eThe mean individual percentage change in UACR was \u0026minus;\u0026thinsp;7.3%. Twenty-two patients (66.7%) responded to treatment with a reduction in UACR, while 11 patients (33.3%) did not. When stratified by baseline albuminuria, responders with initial UACR\u0026thinsp;\u0026lt;\u0026thinsp;1000 mg/g, 1000\u0026ndash;3000 mg/g, and \u0026gt;\u0026thinsp;3000 mg/g showed average reductions of \u0026minus;\u0026thinsp;47.9%, \u0026minus;\u0026thinsp;39.0%, and \u0026minus;\u0026thinsp;32.8%, respectively, suggesting a gradient treatment effect. Finerenone was well tolerated. Mild hyperkalaemia (serum potassium\u0026thinsp;\u0026gt;\u0026thinsp;5.0 mmol/L) occurred in 15.2% of patients, with no cases requiring treatment discontinuation. Renal function remained stable throughout the study.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e\u003cp\u003eFinerenone demonstrated clinically meaningful reductions in proteinuria, particularly in patients with moderate to severe baseline albuminuria, and was generally safe and well tolerated. These findings support the use of finerenone as part of a personalized, multimodal strategy for proteinuria management in diabetic nephropathy, particularly in patients already receiving optimized RAAS and SGLT2 inhibition. Future studies should further define predictors of response and assess long-term renal outcomes.\u003c/p\u003e","manuscriptTitle":"Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and Telmisartan","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-07-18 17:37:01","doi":"10.21203/rs.3.rs-7053853/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ca332062-8ec2-4fd6-87d0-a540e831d736","owner":[],"postedDate":"July 18th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-11-19T10:09:18+00:00","versionOfRecord":[],"versionCreatedAt":"2025-07-18 17:37:01","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7053853","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7053853","identity":"rs-7053853","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}